Stockscreener 앱 받기
3.36
1.01%
-0.10
Cyclerion Therapeutics Inc 주식(CYCN)의 최신 뉴스
Enterprise value to revenue forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Price to sales forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Cyclerion Therapeutics,Inc. Actuals & Estimates (NASDAQ:CYCN) - TradingView
Cyclerion Therapeutics (CYCN) Faces Resistance as Shares Slide Nearly 4%Put Support - dars.gov.et
Cyclerion Therapeutics Inc (CYCN) Institutional Confidence - TradingKey
Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cyclerion Therapeutics Inc (CYCN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cyclerion Therapeutics Inc (CYCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cyclerion Therapeutics Inc (CYCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cyclerion Therapeutics Inc (CYCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cyclerion Therapeutics Inc (CYCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cyclerion Therapeutics Inc (CYCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cyclerion Therapeutics, Inc. announced that it has received $200 million in funding - marketscreener.com
Cyclerion Therapeutics (CYCN) Hovers Near $3.00 as Low Volume Caps MovementDark Pool Volume - newsline.com
Cyclerion (NASDAQ: CYCN) to Merge with Korsana, $380M Pre-Closing Financing - Stock Titan
CYCN Q4 2025 Earnings: Narrowed Loss Surpasses Estimates Amid Pipeline ProgressEarnings Outlook Update - newsline.com
Cyclerion Therapeutics stock soars 350% on Korsana merger, $380 million financing - MSN
Cyclerion Therapeutics (CYCN) Edges Higher Amid Quiet TradingCash Flow Strong Stocks - The Legal Advocate
CYCN Q4 2025 Earnings: Narrowed Losses Exceed Expectations as Development Programs ProgressPre-Earnings Drift - The Legal Advocate
Cyclerion Therapeutics Company Profile & Introduction - Moomoo
CYCNCyclerion Therapeutics Inc Stock Price and Quote - Finviz
Cyclerion Therapeutics (CYCN) Edges Higher as Shares Test Key Resistance LevelsRounding Bottom - The Legal Advocate
Cyclerion Shares to Watch With Deal in Focus as Markets Reopen - Bez Kabli
CYCN Q4 2025 Earnings: Narrowed Loss Beats Street Estimates, Shares ClimbAnnual Report - newsline.com
Cyclerion (CYCN) Delivers Q4 2025 Beat — EPS $-0.21 vs $-0.39 ExpectedTangible Book Value - newsline.com
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
TradingKey - TradingKey
CYCN News | CYCLERION THERAPEUTICS INC (NASDAQ:CYCN) - ChartMill
Why Cyclerion (CYCN) deserves a deeper look right now (-2.78%) 2026-05-07Insider Info - newser.com
FMR LLC holds 15.0% of Cyclerion Therapeutics (NASDAQ: CYCN) in Schedule 13G - Stock Titan
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? - Sahm
CYCN | Cyclerion Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Cyclerion Therapeutics stock soars after strategic Medsteer collaboration By Investing.com - Investing.com Nigeria
Cyclerion Therapeutics 2024 10-K/A Amendment: Executive Compensation, Governance, and Equity Awards Overview - Minichart
Cyclerion Therapeutics (NASDAQ: CYCN) updates board, compensation and PIPE details - Stock Titan
CYCN stock is soaring 150% pre-market today — what is fueling the rally? - MSN
CYCN SEC FilingsCyclerion Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cyclerion Merges with Korsana to Develop Alzheimer Antibody Therapy - HarianBasis.co
Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline - Insider Monkey
5 Unstoppable Stocks That Could Double Your Money - Insider Monkey
Is Cyclerion (CYCN) stock outperforming similar companies (Drifts Higher) 2026-04-18Open Stock Signal Network - Xã Thanh Hà
EDGAR Filing Documents for 0001193125-26-162177 - SEC.gov
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement - Yahoo Finance
Published on: 2026-04-13 23:21:17 - baoquankhu1.vn
Guidance Update: Is Cyclerion Therapeutics Incs growth already priced inEarnings Recap Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time - insights.citeline.com
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders? - Finviz
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Sharehol - GuruFocus
Fed Watch: Is Cyclerion Therapeutics Incs growth already priced inQuarterly Earnings Summary & AI Optimized Trade Strategies - baoquankhu1.vn
1.16%
0.48%
자본화:
|
볼륨(24시간):